Compounds > ofloxacin n-oxide
Page last updated: 2024-12-08

ofloxacin n-oxide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

ofloxacin N-oxide: structure given in first source; analog of ofloxacin [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10362217
CHEBI ID183939
MeSH IDM0155031

Synonyms (20)

Synonym
ofloxacin n-oxide
FT-0673217
7h-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-4-oxido-1-piperazinyl)-7-oxo-
2400mfq95b ,
4-((3rs)-6-carboxy-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7h-pyrido(1,2,3-de)-1,4-benzoxazin-10-yl)-1-methylpiperazine 1-oxide
7h-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, n-oxide, (+/-)-
unii-2400mfq95b
ofloxacin specified impurity f [ep]
ofloxacin n-oxide, (+/-)-
7h-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylicacid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-4-oxido-1-piperazinyl)-7-oxo-
104721-52-0
AKOS030255912
4-[(rs)-6-carboxy-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7h-pyrido[1,2,3-de]-1,4-benzoxazine-10-yl]-1-methylpiperazine 1-oxide hydrochloride (ofloxacin n-oxide hydrochloride)
ofloxacin n-oxide acetic acid salt
7-fluoro-2-methyl-6-(4-methyl-4-oxidopiperazin-4-ium-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
Q27253800
7-luoro-2-methyl-6-(4-methyl-4-oxidopiperazin-4-ium-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
CHEBI:183939
DTXSID801316290
ofloxacin impurity f [ep impurity]

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" In the young and elderly, ofloxacin is eliminated with a half-life of five to seven hours, independent of dose."( Pharmacokinetics of ofloxacin. An overview.
Flor, S, 1989)		0.28
" In 2 patients with chronic renal failure, specific HPLC assay indicated an extended half-life for ofloxacin (approximately 13 hours) and the appearance in serum of low concentrations of both metabolites after 10 hours, persisting until the last blood sample was taken (32 hours)."( A preliminary report on the pharmacokinetics of ofloxacin, desmethyl ofloxacin and ofloxacin N-oxide in patients with chronic renal failure.
Lovering, AM; MacGowan, AP; Mackay, IG; Reeves, DS; White, LO, 1987)		0.27

Dosage Studied

ExcerptRelevanceReference
" The pharmacokinetics of the compound indicate that, except for cases of renal impairment, little or no dosage adjustment is necessary."( Pharmacokinetics of ofloxacin. An overview.
Flor, S, 1989)		0.28
" These results confirm that dosage reduction of ofloxacin is required in haemodialysis patients."( The pharmacokinetics of ofloxacin, desmethyl ofloxacin and ofloxacin N-oxide in haemodialysis patients with end-stage renal failure.
MacGowan, AP; Mackay, IG; Reeves, DS; White, LO, 1988)		0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
quinolinesA class of aromatic heterocyclic compounds each of which contains a benzene ring ortho fused to carbons 2 and 3 of a pyridine ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (50.00)18.7374
1990's2 (33.33)18.2507
2000's1 (16.67)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
ofloxacin
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.. 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.. ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.		3.23603-oxo monocarboxylic acid;
N-arylpiperazine;
N-methylpiperazine;
organofluorine compound;
oxazinoquinoline
desmethylofloxacin
desmethylofloxacin: structure given in first source; analog of ofloxacin		3.2360
ConditionIndicatedRelationship StrengthStudiesTrials
Bacterial Disease
[description not available]		01.9810
Bacterial Infections
Infections by bacteria, general or unspecified.		01.9810
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		0210
Kidney Diseases
Pathological processes of the KIDNEY or its component tissues.		01.9710
Chronic Kidney Failure
[description not available]		02.3720
Kidney Failure, Chronic
The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.		02.3720